title: Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies.
abstract: Neuroleptics have revolutionized the treatment of schizophrenia and other psychoses since the early 1950s. Several adverse neurobiological effects are, however, associated with the long-term use of these agents. This article will review human and animal studies of these adverse effects, and also present some new data. Tardive dyskinesia (TD) is the most widely studied potentially persistent movement disorder resulting from long-term neuroleptic treatment, and several risk factors for TD development have been identified. Although drug-induced parkinsonism (DIP) usually disappears after the offending agent is withdrawn, a small portion of patients may have persistent parkinsonism. It is however, unclear if this is an aging-related effect. Persistent cognitive impairment associated with long-term use of typical neuroleptics has not been well documented. Atypical antipsychotics may produce improvement in cognitive performance in patients with chronic schizophrenia. MRI changes that are secondary to neuroleptics are possible, but have not yet been studied adequately. There is one unconfirmed report of neurofibrillary tangles associated with long-term neuroleptic use. A number of investigators have reported vacuous chewing movements, and neuropathologic changes following prolonged administration of neuroleptics in animals. We discuss the implications of the various reported adverse effects of long-term use of neuroleptics.
authors.affiliation: University of California, San Diego, USA.
authors.forename: D V
authors.initials: DV
authors.lastname: Jeste
authors.forename: J B
authors.initials: JB
authors.lastname: Lohr
authors.forename: J H
authors.initials: JH
authors.lastname: Eastham
authors.forename: E
authors.initials: E
authors.lastname: Rockwell
authors.forename: M P
authors.initials: MP
authors.lastname: Caligiuri
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D009069:Movement Disorders / Q000209:etiology*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents